References
- Allured VS, Collier RJ, Carroll SF, McKay DB. (1986). Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc Natl Acad Sci USA, 83, 1320–1324.
- Davison Z, de Blacquière GE, Westley BR, May FE. (2011). Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia, 13, 504–515.
- Jia LT, Zhang LH, Yu CJ, Zhao J, Xu YM, Gui JH, Jin M, Ji ZL, Wen WH, Wang CJ, Chen SY, Yang AG. (2003). Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3. Cancer Res, 63, 3257–3262.
- Jung J, Matsuzaki T, Tatematsu K, Okajima T, Tanizawa K, Kuroda S. (2008). Bio-nanocapsule conjugated with liposomes for in vivo pinpoint delivery of various materials. J Control Release, 126, 255–264.
- Kasuya T, Jung J, Kadoya H, Matsuzaki T, Tatematsu K, Okajima T, Miyoshi E, Tanizawa K, Kuroda S. (2008). In vivo delivery of bionanocapsules displaying Phaseolus vulgaris agglutinin-L4 isolectin to malignant tumors overexpressing N-acetylglucosaminyltransferase V. Hum Gene Ther, 19, 887–895.
- Kuroda S, Otaka S, Miyazaki T, Nakao M, Fujisawa Y. (1992). Hepatitis B virus envelope L protein particles. Synthesis and assembly in Saccharomyces cerevisiae, purification and characterization. J Biol Chem, 267, 1953–1961.
- Lee SB, Hassan M, Fisher R, Chertov O, Chernomordik V, Kramer-Marek G, Gandjbakhche A, Capala J. (2008). Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res, 14, 3840–3849.
- McLarty K, Cornelissen B, Scollard DA, Done SJ, Chun K, Reilly RM. (2009). Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging, 36, 81–93.
- Nagai T. (2005). Drug discovery and innovative drug delivery research in new drug development. Pharm Tech Japan, 21, 1949–1951.
- Oess S, Hildt E. (2000). Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens. Gene Ther, 7, 750–758.
- Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Höidén-Guthenberg I, Widström C, Carlsson J, Tolmachev V, Ståhl S, Nilsson FY. (2006). Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res, 66, 4339–4348.
- Shishido T, Azumi Y, Nakanishi T, Umetsu M, Tanaka T, Ogino C, Fukuda H, Kondo A. (2009a). Biotinylated bionanocapsules for displaying diverse ligands toward cell-specific delivery. J Biochem, 146, 867–874.
- Shishido T, Yonezawa D, Iwata K, Tanaka T, Ogino C, Fukuda H, Kondo A. (2009b). Construction of arginine-rich peptide displaying bionanocapsules. Bioorg Med Chem Lett, 19, 1473–1476.
- Shishido T, Mieda H, Hwang SY, Nishimura Y, Tanaka T, Ogino C, Fukuda H, Kondo A. (2010). Affibody-displaying bionanocapsules for specific drug delivery to HER2-expressing cancer cells. Bioorg Med Chem Lett, 20, 5726–5731.
- Stoeckl L, Funk A, Kopitzki A, Brandenburg B, Oess S, Will H, Sirma H, Hildt E. (2006). Identification of a structural motif crucial for infectivity of hepatitis B viruses. Proc Natl Acad Sci USA, 103, 6730–6734.
- Tabata T. (2006). Drug delivery system: Basic technology for biomedical research, medical treatment and health care. Biotechnol J, 6, 553–555.
- Yamada T, Iwasaki Y, Tada H, Iwabuki H, Chuah MK, VandenDriessche T, Fukuda H, Kondo A, Ueda M, Seno M, Tanizawa K, Kuroda S. (2003). Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat Biotechnol, 21, 885–890.